The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Arthur He - HC Wainwright & Co. - Analyst
: Hey, good afternoon. How are your team. Thanks for taking my question. So JZ, you read my mind about the by disclosing the dose level for the
AA study. And, so I'm just wondering, so assuming this phase to be starting in the A, can that meets your guys' expectation. How should we think
about the design for when you guys evaluating the maintenance of the in the A patient? Would that follow similar design path as the AD study?
Question: Arthur He - HC Wainwright & Co. - Analyst
: So just a quick one, on the technical side for the study design for the alopecia study. So I noticed that, for those patients did not reach aAR score
less than 20, they can get an additional 16 week treatment, right? So the, those patients will also be followed in an additional 24 weeks. So, is that
right? Or I mean, for that thing, those patients' kind of the total study time period will be a little bit longer.
Question: Arthur He - HC Wainwright & Co. - Analyst
: Okay, got it, yeah.
Question: Jessica Fye - JPMorgan - Analyst
: Hey guys, good afternoon. Thanks for taking my question. Is it fair to expect that you would wait for the 36 week AD data before pursuing an end
phase two meeting with FDA and preparing to initiate a phase 3 trial, or is there potentially motivation to meet with the FDA sooner on the back
of this upcoming data and get the ball rolling on phase 3 that much sooner?
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
MAY 08, 2025 / 9:00PM, NKTR.OQ - Q1 2025 Nektar Therapeutics Earnings Call
Thank you.
Question: Jessica Fye - JPMorgan - Analyst
: Thank you.
|
